English
中文繁體中文EnglishFrançaisDeutsch日本語PortuguêsEspañolالعربيةРусскийBahasa IndonesiaไทยTiếng ViệtBahasa Melayu
Keshav Medicine KESHAV
Today Deal Hot Cart (0)
NEWS DETAIL

Syndax a annoncé la publication dans le *Journal of Clinical Oncology* des données de l’étude SAVE concernant Revuforj® (revumenib) en association avec la décitabine/cidazaril et le vénétoclax pour le traitement des LAM NPM1m, KMT2Ar et NUP98r en rechute ou réfractaires. —GlobeNewswire

Syndax a annoncé la publication des données de l'étude SAVE dans le *Journal of Clinical Oncology* concernant Revuforj® (revumenib) en association avec la décitabine/cidazolidine e…

Informations médicales

该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

Products Mentioned in This Article

These products were automatically matched from the article title, summary, and full content.

Lucius Revumenib online purchase

Lucius Revumenib online purchase

USD 261.33 – USD 1,381.33Price range: USD 261.33 through USD 1,381.33
FDA Label Product: Revuforj. Active Ingredient/Generic Name: REVUMENIB. Company: Syndax Pharmaceuticals, Inc. Route of Administration: ORAL. Main Indications: 1. INDICATIONS AND USAGE: REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. (1) the t
View Product

Frequently Asked Questions

Which products are related to this article?

The system matched these relevant products from the article content: Lucius Revumenib online purchase.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp WeChat WeChat